Log In
BCIQ
Print this Print this
 

Osmolex ER (OS-320)

  Manage Alerts
Collapse Summary General Information
Company Osmotica Pharmaceutical Corp.
DescriptionExtended-release formulation of amantadine using Osmodex technology
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat levodopa induced dyskinesia (in patients with Parkinson's disease (PD)
Regulatory Designation U.S. - Orphan Drug (Treat levodopa induced dyskinesia (in patients with Parkinson's disease (PD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today